Lantern Pharma (NASDAQ: LTRN) has announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026. The event will feature two sessions to accommodate global audiences and will be led by CEO Panna Sharma. The demonstration will showcase the platform's ability to execute complex oncology research workflows by integrating clinical, molecular, and scientific datasets in real time.
The withZeta.ai platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model. According to the company, this represents a new revenue stream for Lantern Pharma, which is already advancing a clinical pipeline of precision oncology candidates.
Lantern's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
WithZeta.ai is now commercially available as a subscription-based research platform for the global biomedical and drug development community. The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. This live demonstration marks a significant step in the adoption of AI-driven drug discovery tools, as Lantern seeks to prove the practical utility of its platform to potential subscribers.
The implications of this announcement are substantial for the Texas-based biotech industry and beyond. By demonstrating the practical utility of withZeta.ai, Lantern Pharma could accelerate drug discovery timelines, particularly for rare cancers with high unmet medical needs. The platform's ability to integrate clinical, molecular, and scientific datasets in real time could reduce the time and cost associated with traditional drug development. For the biomedical community, this could mean faster access to novel therapies. For investors, the subscription-based model offers a new revenue stream that may enhance Lantern Pharma's financial stability and growth prospects. The live event will be a critical test of the platform's capabilities and could influence broader adoption of AI-driven tools in drug development.
For more information, the full press release is available at https://ibn.fm/wzevl. Additional updates on the company can be found in its newsroom at https://ibn.fm/LTRN.
